12-1: Rapid Review Ii

Front 1

Why should splenectomy pts be vaccinated?

Vaccinated against what?

Back 1

Splenic white pulp filters Ag's; impt for response to encapsulated orgs

Esp H flu
Meningococcus
Pneumococcus

Front 2

Normal Myeloid:Erythroid ratio.

Back 2

2-3:1 (2-3 myeloid cells for every erythroid cell)

Front 3

Increased M:E ratio

Back 3

CML

Front 4

Philadelphia chromosome

Back 4

CML (chrom 22)

Front 5

210 BCR-ABL

Back 5

95% CML

Front 6

190 BCR-ABL

Back 6

20% ALL, CML w/monocytosis

Front 7

CML:
Chronic Phase

Back 7

Leukocytosis w/all stage nphil dev't, basophilia

LOW LAP SCORE

Front 8

Low LAP score

Back 8

CML

Front 9

Imatinib: MOA

Back 9

Occupies kinase pocket of BCR-ABL prot

Front 10

Dasatinib

Back 10

2nd generation tx for CML

Front 11

Nilotinib

Back 11

2nd generation tx for CML

Front 12

CLL transformation

Back 12

80% AML, 20%ALL

Front 13

MPDs involve what cell?

Back 13

Pleuripotent Stem Cell

PCV, ET, Idiopathic Myelofibrosis

Front 14

HCT>50%, Low EPO

Back 14

PVera

Front 15

100% JAK-2 Mutations

Back 15

PVera (autophosphorylate sans EPO)

Front 16

PVera:
Polycythemic Myeloid Metaplasia Phase
-Pathophys

Back 16

Collagen deposition and scarring in marrow lead to BM failure w/pancytopenia, can transform to CML

Front 17

PVera transformations

Back 17

CML

Front 18

50% JAK-2 Mutations

Back 18

Essential Thrombocytosis

Front 19

Essential Thrombocytosis:
Treatment

Back 19

Low risk: Low dose ASA
High risk (>60, hx clot+): low dose ASA, hydrea

Front 20

Idiopathic myelofibrosis:
Pathophys

Back 20

Collagen deposition due to dysmegakaryopoiesis resulting in inc'd PDGF-->Inc'd prolifertn fibroblasts and collagen deposition

Leads to scarring of marrow

Front 21

Bone marrow aspirate cannot be obtained (dry tap)

Back 21

Idiopathic myelofibrosis --due to extensive marrow scarring

Front 22

>20% blasts

Back 22

Acute LEUKEMIA

Front 23

Acute vs Chronic Leukemias: General

Back 23

Chronic leukemias do NOT have >20% blasts in marrow

Front 24

Auer rods

Back 24

AML

Front 25

Tdt-
CD13+
CD33+

Back 25

AML

Front 26

Tdt+
CD19+
CD20+

Back 26

B-Cell ALL

Front 27

Tdt+
CD2+
CD5+
CD7+

Back 27

T-Cell ALL

Front 28

t(15, 17)

Back 28

APML

Front 29

Faggot Cells

Back 29

APML

Front 30

AML associated w/Down's

Back 30

M7: megakaryoblastic

Front 31

Non-Specific Esterase

Back 31

M4: myelomonocytic
M5: monocytic

Front 32

t(16; 16)
t(8;21)
t(15; 17)

Back 32

Good prognostic factors for AML

Front 33

AML:
Treatment

Back 33

7+3

7 Days cytarabine (AraC)
3 Days anthracycline (adriamycin, daunorubicin)

Risk:
If good risk: 3-4 cycles AraC
Intermediate: Allogeneic or Autlogous SCT
Poor: Allogeneic SCT

Front 34

ATRA:
MOA

Back 34

AMPL:
ATRA binds PML-RAR and instead of HDAT binding, HAT binds and allows acetylation of histones. Differentiation resumes.

Front 35

ATRA Syndrome

Back 35

Capillary leak syndrome-->fever, respiratory distress, fluid retention

Front 36

MIAMI

Back 36

Malignancy: lypmhoma, leukemia, Kaposi's, mets

Infection: HIV, mono, TB

Autoimmune: SLE, RA

Misc: Kawasaki, sarcoid

Iatrogenic: Dilantin, serum sickness

Front 37

Bimodal age distribution

Back 37

15-24; >55

Hodgkin's

Front 38

CD15+
CD30+

Back 38

Classical HL

Front 39

Lacunar Cells

Back 39

Nodular Lymphoma

Front 40

CD15-
CD30-
CD20+

Back 40

Non-Classical HL

Front 41

Hodgkin's Lymphoma:
Treatment

Back 41

ABVD
Adriamycin -- cardiotox
Bleomycin --Pulm fibrosis
Vinblastine --anti-MT
Dacarbazine --alk

Front 42

HL vs NHL:
which more common?

Back 42

NHL

Front 43

NHL:
EBV related

Back 43

Burkitt's
HIV related
NK/T cell

Front 44

t(14;18)

Back 44

Follicular lymphoma:
bcl-2 overexpression

Front 45

CD10+
CD20+
CD22+
CD5-

Back 45

Follicular (INDOLENT) NHL
bcl-2 +

Front 46

CD23+
CD5+

Back 46

SLL

Front 47

SLL transformations

Back 47

Prolymphocytic
DLBCL

Front 48

SLL:
Treatment

Back 48

Initial: WW
Syx: FRCVP
Fludaramine
Rituximab
Cyclophosphamide
Vincristine
Prednisone

Front 49

CD19+
CD20+
CD23+
CD5+

Back 49

CLL

Front 50

CLL transformations

Back 50

Prolymphocytic leukemia
DLBCL

Front 51

Rai classification

Back 51

For CLL!!!!!

Stage 0 - lymphocytosis
Stage 1 - w/LAD
Stage 2 - w/organomegaly
Stage 3 - w/anemia
Stage 4 - w/thrombocytopenia

Front 52

17p deletion

Back 52

WORST prognosis in CLL/SLL

Front 53

ZAP70/CD38

Back 53

Prognosis in CLL/SLL

Front 54

CLL results in anemia for 2 reasons. What are they?

Back 54

Autoimmune hemolytic anemia (abnl B cells produce Abs x RBC/PLTs)

Extensive BM involvement

Front 55

CD20+
CD5-
CD10-

Back 55

Marginal Zone Lymphoma

Front 56

t(11;18)

Back 56

MALT

Front 57

t(8;14)

Back 57

Burkitt's

Front 58

Tdt-
CD10+
CD20+

Back 58

Burkitt's

Front 59

Ki67

Back 59

Burkitt's

Front 60

t(11;14)

Back 60

Mantle Cell
bcl-1 gene mutation-->cyclin D1 overexpression

Front 61

Tdt-
CD19+
CD20+

Back 61

DLBCL

Front 62

DLBCL:
Treatment

Back 62

RCHOP

Rituximab
Cyclophosphamide
Daunorubicin
Vincristine
Prednisone